Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 65/100

Termination Rate

20.0%

1 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
P 2 (1)
P 3 (1)
P 4 (2)

Trial Status

Unknown3
Terminated1
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT04887831Phase 2Terminated

Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab

NCT06665737Phase 4Not Yet Recruiting

Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients

NCT04504513UnknownPrimary

Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer

NCT03793205Phase 4Unknown

G-CSF for the Prevention of Febrile Neutropenia in Gynecologic Cancer Patients

NCT03740464Phase 3Unknown

Long-acting G-CSF for Febrile Neutropenia

Showing all 5 trials

Research Network

Activity Timeline